The Experts below are selected from a list of 13875 Experts worldwide ranked by ideXlab platform
Florian Guisier - One of the best experts on this subject based on the ideXlab platform.
-
Crizotinib-induced Osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ould-slimane, Hélène Morisse-pradier, M. SalaunAbstract:BACKGROUND: Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. CASE PRESENTATION: A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. CONCLUSIONS: This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
-
crizotinib induced Osteitis mimicking bone metastasis in a stage iv alk rearranged nsclc patient a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ouldslimane, Helene MorissepradierAbstract:Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
Helene Morissepradier - One of the best experts on this subject based on the ideXlab platform.
-
crizotinib induced Osteitis mimicking bone metastasis in a stage iv alk rearranged nsclc patient a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ouldslimane, Helene MorissepradierAbstract:Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
M. Salaun - One of the best experts on this subject based on the ideXlab platform.
-
Crizotinib-induced Osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ould-slimane, Hélène Morisse-pradier, M. SalaunAbstract:BACKGROUND: Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. CASE PRESENTATION: A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. CONCLUSIONS: This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
Nicolas Delberghe - One of the best experts on this subject based on the ideXlab platform.
-
Crizotinib-induced Osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ould-slimane, Hélène Morisse-pradier, M. SalaunAbstract:BACKGROUND: Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. CASE PRESENTATION: A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. CONCLUSIONS: This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
-
crizotinib induced Osteitis mimicking bone metastasis in a stage iv alk rearranged nsclc patient a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ouldslimane, Helene MorissepradierAbstract:Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
Olivier Vittecoq - One of the best experts on this subject based on the ideXlab platform.
-
Crizotinib-induced Osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ould-slimane, Hélène Morisse-pradier, M. SalaunAbstract:BACKGROUND: Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. CASE PRESENTATION: A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. CONCLUSIONS: This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
-
crizotinib induced Osteitis mimicking bone metastasis in a stage iv alk rearranged nsclc patient a case report
BMC Cancer, 2020Co-Authors: Florian Guisier, Nicolas Piton, Marie Bellefleur, Nicolas Delberghe, Gilles Avenel, Emilie Angot, Olivier Vittecoq, Mourad Ouldslimane, Helene MorissepradierAbstract:Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we report a case of Osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously undescribed side effect of crizotinib. A 31-year-old woman with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of crizotinib treatment. Diagnostic work-up showed Osteitis on the 4th and 5th thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any sign of infection. Spinal cord decompression, histological removal and osteosynthesis were performed. Histologic examination showed necrosis with abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib withdrawal and did not recur after ceritinib onset. This is the first report of crizotinib-induced Osteitis. Crizotinib differs from other ALK inhibitors as it targets other kinases as well, which may have been responsible for the Osteitis. Crizotinib can induce rapidly extensive Osteitis, which can mimic tumor progression.
